GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » Cyclically Adjusted PB Ratio

XTL Biopharmaceuticals (XTL Biopharmaceuticals) Cyclically Adjusted PB Ratio : 1.49 (As of May. 15, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-15), XTL Biopharmaceuticals's current share price is $2.57. XTL Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.73. XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio for today is 1.49.

The historical rank and industry rank for XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

XTLB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.24   Max: 1.92
Current: 1.74

During the past years, XTL Biopharmaceuticals's highest Cyclically Adjusted PB Ratio was 1.92. The lowest was 0.08. And the median was 0.24.

XTLB's Cyclically Adjusted PB Ratio is ranked better than
53.8% of 645 companies
in the Biotechnology industry
Industry Median: 1.79 vs XTLB: 1.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

XTL Biopharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $0.407. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.73 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


XTL Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Cyclically Adjusted PB Ratio Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 1.29 1.14 0.60 0.60

XTL Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.64 0.59 0.59 0.60

Competitive Comparison of XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.



XTL Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.57/1.73
=1.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, XTL Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.407/129.4194*129.4194
=0.407

Current CPI (Dec. 2023) = 129.4194.

XTL Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 2.637 99.695 3.423
201406 2.451 100.560 3.154
201409 1.972 100.428 2.541
201412 1.704 99.070 2.226
201503 1.695 99.621 2.202
201506 2.789 100.684 3.585
201509 2.641 100.392 3.405
201512 1.787 99.792 2.318
201603 1.602 100.470 2.064
201606 1.489 101.688 1.895
201609 1.395 101.861 1.772
201612 0.980 101.863 1.245
201703 0.681 102.862 0.857
201706 0.406 103.349 0.508
201709 0.704 104.136 0.875
201712 0.704 104.011 0.876
201803 1.205 105.290 1.481
201806 1.213 106.317 1.477
201809 1.414 106.507 1.718
201812 1.414 105.998 1.726
201903 2.372 107.251 2.862
201906 1.817 108.070 2.176
201909 1.573 108.329 1.879
201912 1.267 108.420 1.512
202003 1.366 108.902 1.623
202006 1.283 108.767 1.527
202009 1.172 109.815 1.381
202012 0.702 109.897 0.827
202103 0.849 111.754 0.983
202106 0.621 114.631 0.701
202109 0.569 115.734 0.636
202112 0.979 117.630 1.077
202203 1.072 121.301 1.144
202206 1.021 125.017 1.057
202209 0.871 125.227 0.900
202212 0.734 125.222 0.759
202303 0.565 127.348 0.574
202306 0.499 128.729 0.502
202309 0.459 129.860 0.457
202312 0.407 129.419 0.407

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XTL Biopharmaceuticals  (NAS:XTLB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


XTL Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Executives
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Samuel Rudman director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ben-zion Weiner director 3 HAYOGEV STREET, MOSHAV MAZOR L3 73160
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Michael Cho 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott Bradley 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
William Kessler officer: Director of Finance C/O XTL BIOPHARMACEUTICALS LTD., 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ron Bentsur officer: CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989